
|Articles|October 25, 2013
- Genitourinary Cancers
- Volume 1
- Issue 1
Frontline Treatment of Kidney Cancer With Pazopanib and Sunitinib
Author(s)James J. Hsieh, MD, PhD
James J. Hsieh, MD, PhD, medical oncologist, Memorial Sloan-Kettering Cancer Center, discusses the frontline treatment of patients with kidney cancer with pazopanib and sunitinib.
James J. Hsieh, MD, PhD, medical oncologist, Memorial Sloan-Kettering Cancer Center, discusses the frontline treatment of patients with kidney cancer with pazopanib and sunitinib.
The development of drugs that target angiogenesis and signal transduction pathways in the treatment of metastatic renal cell carcinoma has led to improved survival rates for patients.
Articles in this issue
almost 12 years ago
Patient-Centered Management of Metastatic Renal Cell Carcinomaalmost 12 years ago
Expert Perspectives: Androgen-Deprivation Therapy in Prostate Cancerabout 12 years ago
Treatment of Advanced Renal Cell Carcinomaabout 12 years ago
Treatment Pathways and Sequencing Strategies in CRPCabout 12 years ago
Therapeutic Strategies for Managing Bone Health in Prostate Cancerabout 12 years ago
Immunotherapy in CRPCabout 12 years ago
Factors in Choosing First-Line Targeted Therapy in RCCabout 12 years ago
Immune Response in Patients with RCCabout 12 years ago
Sequencing Agents to Treat Castration-Resistant Prostate Cancer





































